Diabetes Advocacy Training
This is where members learn how to meet with their legislators and develop skills to advocate for diabetes care and education.
Participate in Advocacy Training
Each year, we host multiple opportunities for our member advocates to obtain training on diabetes advocacy.
Our two largest events are the Public Policy Forum & Hill Day and the State Policy Forum. These premier events feature expert speakers on key issues related to diabetes care and prevention that are actively being considered at the state and federal levels.
As part of diabetes advocacy training, attendees learn about current issues, policy goals that the diabetes community is seeking to address, how to talk with legislators and their staff, and how to develop partnerships to push for change.
Advocacy training events are for ADCES® members with all levels of advocacy experience and have no cost to register.
Diabetes Advocacy Training
Public Policy Forum
Public Policy Forum & Hill Day
2025 Public Policy Forum & Hill Day
The ADCES Public Policy Forum (PPF) and Hill Day are returning virtually in 2025. This free event is open to all ADCES members with any level of advocacy experience – from beginner to expert.
Registration for PPF is now closed. We hope to see you next year!
- Virtual PPF training: June 11, 12:00 p.m. – 5:00 p.m. ET
- Virtual Hill Day: June 12. Congressional meeting times will vary.
- ADCES Advocacy priorities and 2025 activities
- The state of diabetes policy in Washington
- Legislative training on key legislation
- Preparing for Congressional meetings including team breakouts
- Expanding Access to Diabetes Self-Management Training Act
- Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services (DIABETES) Act
- Medicare Payment Reform
- Veronica Brady, PhD, RN, BC-ADM, CDCES, 2025 ADCES President
- Hannah Martin, MPH, RDN, Director of Advocacy, ADCES
- Tiffani Williams, JD, MPH, The Daschle Group
- Sheila Burke, MPA, BSN, FAAN, Baker Donelson
- Brian Lee, JD, MPH, Alston & Bird
- Rebecca Spangler, American College of Radiology
- Janet Benefield, MS, RD, LD, CDCES, ADCES Advocacy Committee Chair
- Andrea McCarty, MS, RDN, LDN, CDCES, BC-ADM, ADCES Advocacy Committee Member
- Gina R. Ward, MS, RD, CDCES, ADCES Advocacy Committee Member
2025 Public Policy Forum Resources
Below are links to resources related to the Public Policy Forum.
From Lilly: EveryBODY Covered
From Lilly: Lilly Insulin Value Program | Lilly Insulin Affordability
Thank You, Sponsors!
State Policy Forum
2024 State Policy Forum
This free event, held on September 24, 2024, was open to all ADCES members with any level of advocacy experience – from beginner to expert. You can watch the event recording here.
- September 24, 12:30 p.m. – 5:00 p.m. ET
- The importance of Medicaid advocacy for health equity
- Training on key Medicaid coverage issues
- Grassroots panel
- State networking breakouts
- Diabetes self-management education and support
- Continuous glucose monitors
- Obesity medications
- Jane K. Dickinson, RN, PhD, CDCES, 2024 ADCES President
- Hannah Martin, MPH, RDN, Director of Advocacy, ADCES
- Rachel J Thornton, MD, PhD, Vice President and Chief Health Equity Officer, Nemours Children’s Health
- Joe Moser, Independent Consultant, former Medicaid Director, Indiana
- Carissa Kemp, MPP, Senior Director of Policy, American Diabetes Association
- Lauren Pickens, MS, RDN, Public Policy Coordinator, Colorado Academy of Nutrition and Dietetics
- Anastasia Albanese-O’Neill, PhD, APRN, CDCES, ADCES Advocacy Committee Member
- Michelle Dennison, PhD, RD/LD, BC-ADM, CDCES, Vice-President, Policy and Prevention, Oklahoma City Indian Clinic
- Teresa Martin, MS, RDN, LD, CDCES, Chair, ADCES Advocacy Committee
2024 State Policy Forum Resources
- Event Agenda
- Speaker Bios
- From Dexcom: Medicaid Coverage Overview for CGMs – Aug. 2024
- From Dexcom: Medicaid CGM Policy Scorecard – Aug. 2024
- From Lilly: Global Data State Obesity Scorecards
Thank You, Sponsors!
Thank you to our 2024 State Policy Forum sponsors, Abbott, Dexcom, Lilly and Novo Nordisk.